Home / Health / Malaria Jab Trial Launches in Rwanda

Malaria Jab Trial Launches in Rwanda

3 Nov

Summary

Rwanda begins trial for first long-acting malaria prevention injection.
The experimental compound, MMV371, aims for year-long protection.
Successful trials could significantly aid malaria control efforts.

A significant step forward in the fight against malaria is being taken as Rwanda launches a trial for the first-ever long-acting injectable meant to prevent the disease. This innovative compound, identified as MMV371, is designed to provide protection for an entire year after a single administration.

The trial's success could mark a pivotal moment in malaria control strategies worldwide. The development of such an injectable represents a crucial advancement, offering a promising new weapon against this widespread mosquito-borne illness.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.